More than one-third of adults in the USA have obesity, which causes, exacerbates or adversely impacts numerous medical comorbidities, including diabetes mellitus and cardiovascular disease. Despite intensive lifestyle modifications, the disease severity warrants further aggressive intervention, including pharmacotherapy, medical devices and bariatric surgery. Noninvasive anti-obesity drugs have thus now resurfaced as targeted adjunctive therapeutic approaches to intensive lifestyle intervention, bridging the gap between lifestyle and bariatric surgery. In this Review, we discuss FDA-approved anti-obesity drugs in terms of safety and efficacy. As most of these drugs have a mean percentage weight loss reported in clinical trials but individual variations in response rates, a future direction of obesity pharmacotherapy research might include the potential for personalized medicine to target early responders to these anti-obesity drugs.

在美国，超过三分之一的成年人患有肥胖症，肥胖症会导致，加剧或不利地影响包括糖尿病和心血管疾病在内的多种医学合并症。尽管对生活方式进行了大量修改，但疾病的严重程度仍需要进一步积极干预，包括药物治疗，医疗设备和减肥手术。因此，无创抗肥胖药现在已经成为针对强化生活方式干预的有针对性的辅助治疗方法，从而缩小了生活方式与减肥手术之间的差距。在本综述中，我们从安全性和有效性方面讨论了FDA批准的抗肥胖药。由于大多数此类药物在临床试验中均报告了体重减轻的平均百分比，但反应率存在个体差异，